Ravi Patel, MD
Hematology & Oncology · Bedford, TXNPI 1366736969
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (55.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Novartis at 56.5% of the total. 2025 is the largest year on record at $1,484, more than ten times the $133 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in TX, where the typical reported total is $3,204.
Across 51 payments — averaging $42.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- AbbVie$138
- AstraZeneca$116
- Incyte Corporation$100
- Beone Medicines USA, Inc.$81
- Pfizer$70
- plus $434 from 11 others
Across 3 payments — averaging $4890.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$14K
- AstraZeneca$666
What the payments were for
- Food & beverage$75335%
- Education$20610%
- Other$1,19655%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 13 | $1,218 |
| AbbVie | 5 | $138 |
| AstraZeneca | 3 | $116 |
| Incyte Corporation | 1 | $100 |
| Beone Medicines USA, Inc. | 3 | $81 |
| Pfizer | 4 | $70 |
| Siemens Medical Solutions USA, Inc. | 4 | $60 |
| Daiichi Sankyo Inc. | 2 | $55 |
| Johnson & Johnson | 2 | $50 |
| Bristol Myers Squibb | 2 | $43 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $42 |
| Gilead(2 entities) | 3 | $41 |
| GSK | 2 | $36 |
| Beigene USA, Inc. | 2 | $33 |
| CTI Biopharma Corp. | 1 | $28 |
| Stemline Therapeutics Inc. | 1 | $26 |
| Pharmaessentia USA Corporation | 1 | $20 |
How this compares
$2,156 in reported general payments places this provider in the 40th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 11 | $259,744 |
| RevlimidLenalidomide | 12 | $210,674 |
| CalquenceAcalabrutinib Maleate | 13 | $182,909 |
| ErleadaApalutamide | 12 | $179,142 |
| EliquisApixaban | 60 | $46,209 |
| XareltoRivaroxaban | 36 | $37,956 |
| Exemestane | 13 | $3,603 |
| Tamoxifen Citrate | 72 | $2,419 |
| Anastrozole | 120 | $1,974 |
| Hydroxyurea | 12 | $1,055 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 33 | $1,014 |
| Letrozole | 30 | $913 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 32 | $494 |
| Acyclovir | 30 | $345 |
| Gabapentin | 31 | $279 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali | $1,218 | $259,74411 claims |
| Johnson & JohnsonErleada, Xarelto | $50 | $217,09948 claims |
| Bristol Myers SquibbRevlimid | $43 | $210,67412 claims |
| AstraZenecaCalquence | $116 | $182,90913 claims |
| PfizerEliquis | $70 | $46,20960 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Bedford
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Asad DeanFort Worth$1.1M
- Habte YimerTyler$934K
- Edward PearsonDallas$900K
- Naval DaverHouston$853K
- Christopher MaiselDallas$713K
- Clifton LaymanEl Paso$645K
- Jorge Cortes-FrancoHouston$627K
- Timothy FenskeSan Antonio$626K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.